Intelligence Feed event · Policy · 2026-10-01

    Theriva Biologics Publishes Phase 2b Pancreatic Cancer Trial Data in Nature Medicine

    Question

    Theriva Biologics Publishes Phase 2b Pancreatic Cancer Trial Data in Nature Medicine

    Direct answer

    Theriva Biologics announced the formal peer-reviewed publication of its Phase 2b VIRAGE trial in Nature Medicine. The trial investigated VCN-01 in combination with standard chemotherapy for first-line metastatic pancreatic ductal adenocarcinoma. The published data demonstrated statistically meaningful extensions in overall survival and progression-free survival, supporting clinical advancement in an oncology indication with historically limited treatment alternatives.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Theriva Biologics Publishes Phase 2b Pancreatic Cancer Trial Data in Nature Medicine”, revision 1, evidence through 2026-10-01. https://marketontology.com/market-events/2026-10-01/theriva-biologics-publishes-phase-2b-pancreatic-cancer-trial-data-in-nature-medi-903fd1

    POLICY
    Theriva Biologics Publishes Phase 2b Pancreatic Cancer Trial Data in Nature Medicine
    Theriva Biologics announced the formal peer-reviewed publication of its Phase 2b VIRAGE trial in Nature Medicine. The trial investigated VCN-01 in combination with standard chemotherapy for first-line metastatic pancreatic ductal adenocarcinoma. The published data demonstrated statistically meaningful extensions in overall survival and progression-free survival, supporting clinical advancement in an oncology indication with historically limited treatment alternatives.
    TOVX
    Impact
    67
    OCT 1
    SIG
    80%
    TOVX
    Theriva Biologics Publishes Phase 2b Pancreatic Cancer Trial Data in Nature Medicine
    Theriva Biologics announced the formal peer-reviewed publication of its Phase 2b VIRAGE trial in Nature Medicine. The trial investigated VCN-01 in combination with standard chemotherapy for first-line metastatic pancreatic ductal adenocarcinoma. The published data demonstrated statistically meaningful extensions in overall survival and progression-free survival, supporting clinical advancement in an oncology indication with historically limited treatment alternatives.
    → Peer-reviewed Phase 2b oncological efficacy validation de-risks developmental pipeline valuation for TOVX oncology assets.
    Impact
    Theriva Biologics announced the formal peer-reviewed publication of its Phase 2b VIRAGE trial in Nature Medicine. The trial investigated VCN-01 in combination with standard chemotherapy for first-line metastatic pancreatic ductal adenocarcinoma. The published data demonstrated statistically meaningful extensions in overall survival and progression-free survival, supporting clinical advancement in an oncology indication with historically limited treatment alternatives.
    Affected
    TOVX
    Transmission
    Peer-reviewed Phase 2b oncological efficacy validation de-risks developmental pipeline valuation for TOVX oncology assets.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    TOVXclinical pipeline derisking via peer-reviewed Phase 2b oncology survival dataUp1-4wNature Medicine publication showing improved OS and PFS in metastatic pancreatic cancer.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month